In addition, USP4 can directly interact with TGF-β receptor type I (TGFR-1) through deubiquitination and activate the TGF-β signaling pathway, which can induce EMT in hepatoma cells, providing a new therapeutic target for the treatment of HCC (152). Here, TGFBR1 is linked to hepatocellular carcinoma.